Loading
VNX-102 is an experimental in vivo gene therapy from Vironexis Biotherapeutics, in preclinical development for multiple myeloma.
VNX-102 is an in vivo gene therapy (TransJoin vectorised T-cell engager) from Vironexis Biotherapeutics. A TransJoin vectorised T-cell engager programme against BCMA and GPRC5D for multiple myeloma. Its furthest stage is preclinical development, for multiple myeloma. No clinical trial naming it is registered on ClinicalTrials.gov. Company milestone: '2026-Q1 IND enabling studies available'. It has not been shown to work in people.
1.One arm of VNX-102 binds BCMA on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VNX-102" OR ABSTRACT:"VNX-102") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VNX-102, not a curated reading list.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares BCMA and the tag pipeline.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares GPRC5D and the tag pipeline.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares GPRC5D and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/